NPA Advocates for US Supplement Industry on Capitol Hill, Targets MPL Bill

Washington D.C., United States — 14 May 2026

The Natural Products Association (NPA) hosted its annual 'Fly-In Day', bringing over 180 members to Capitol Hill for direct engagement with US lawmakers. This initiative focused on critical legislative and regulatory priorities for the dietary supplement industry. A primary objective was to actively oppose the proposed Mandatory Product Listing (MPL) bill, which industry leaders argue would introduce unnecessary bureaucratic hurdles and disincentivise innovation. Manufacturers are particularly concerned about the potential for increased compliance costs and disclosure requirements that could strain resources, especially for small to medium-sized businesses.

Another key agenda item involved advocating for a modernisation of the drug preclusion clause. The current interpretation can restrict the use of ingredients with prior drug approval in dietary supplements, even if they have a history of safe use as food or supplements. Reformulating this clause is vital for expanding the scope of permissible ingredients, offering greater flexibility for product development and broadening the range of supplements available to consumers. This reform could accelerate ingredient approvals, reducing lead times for new product launches by up to a year.

Further discussions centred on expanding consumer access to dietary supplements through Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs). Inclusion in these programmes would significantly enhance affordability and accessibility, potentially driving substantial market growth for supplement brands. The NPA also pressed for clearer definitions of the Food and Drug Administration's (FDA) authority, particularly in light of varied state-level regulatory actions concerning natural products. This fragmentation creates compliance complexities for manufacturers operating across multiple states. Clear federal guidelines would streamline regulatory adherence and reduce legal risks.

What this means for United States

US supplement manufacturers and brand owners face immediate commercial implications from these legislative efforts. The ongoing threat of the MPL bill necessitates pre-emptive compliance strategy development to mitigate potential registration costs and data reporting burdens, which could compress margins by 3-5%. Successful modernisation of the drug preclusion clause will open new reformulation windows and allow for the integration of previously restricted, beneficial ingredients, offering a competitive advantage. Furthermore, gaining HSA/FSA eligibility for supplements would dramatically expand the consumer base, requiring marketing and sales teams to adjust strategies to target these new purchasing channels and their associated consumer demographics, potentially increasing sales by 10% within the first year of implementation.

Brands should monitor legislative developments closely and consider engaging with industry advocacy groups to influence policy outcomes. Supply chain procurement leads must assess ingredient portfolios for new opportunities arising from clarification of the drug preclusion clause.

Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.